Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.

Cancer reports (Hoboken, N.J.) - 1 Mar 2024

Blas Page E, Rodriguez Esther San Roman, Williams Heather L, Levin Maren K, Bell Joshua S K, Pierobon Mariaelena, Barrett Alexander S, Petricoin Emanuel F, O'Shaughnessy Joyce A

Abstract excerpt

BACKGROUND: Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2-positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2, and HER3 that are predicted to enhance HER2 downstream pathway activation in a HER2-dependent manner. METHODS: In this report, we present two exceptional responses in hormone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38441358
DOI: 10.1002/cnr2.1954
PMCID: PMC10913072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.PMID 38441358Read ↗

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.Semantic proximity Read ↗

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read ↗

Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.Semantic proximity Read ↗

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.Semantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.